Previous trials with TCN-P, page-11

"This more recent 2011 study is relevant to the combination theory and references TCN-P:
https://clincancerres.aacrjournals.org/content/17/9/2852.full"

Biochemistry, In vitro or "In an ErbB2-driven breast tumor transgenic mouse model"... As I pointed out, the 70s studies by the NCBI already showed TCN-P was potent against cancer cell lines... now the Moffitt Centre in 2011 has shown TCN-P to be potent in combination with other compounds? I fail to understand the relevance.

This study is from 2008 and also looks at combination therapy https://ash.confex.com/ash/2008/webprogram/Paper13567.html

- No, it's a poster hung up on a wall in a conference center. Look at the authors...
"M.D. Anderson Cancer Center, Houston, TX"
"Moffitt Cancer Ctr. & Rsrch. Institute, Tampa, FL"
"VioQuest Pharmaceuticals, Inc., Basking Ridge, NJ"
and look where the funding came from.
- it screams of "we're desperate". No scientist will take the results and interpretation presented on that poster seriously.

Here's the link to the published results:
http://www.ncbi.nlm.nih.gov/pubmed/23993427

Published in November 2013, about 5 years after the poster presentation... what took so long?

The ticker code for VioQuest is VOQP on the US OTC markets. Wonder what happened with the trial